Lung function parameters in omalizumab responder patients: An interesting tool?

Paganin F.; Mangiapan G.; Proust A.; Prudhomme A.; Attia J.; Marchand‐Adam S.; Pellet F.; Milhe F.; Melloni B.; Bernady A.; Raspaud C.; Nocent C.; Berger P.; Guilleminault L.

首页> 外文期刊>Allergy >Lung function parameters in omalizumab responder patients: An interesting tool?

【24h】

Lung function parameters in omalizumab responder patients: An interesting tool?

机译：omalizumab响应者患者中的肺功能参数：一个有趣的工具？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Abstract Background Omalizumab, an anti‐IgE antibody, is used to treat patients with severe allergic asthma. The evolution of lung function parameters over time and the difference between omalizumab responder and nonresponder patients remain inconclusive. The objective of this real‐life study was to compare the changes in forced expiratory volume in 1?second ( FEV 1) of omalizumab responders and nonresponders at 6?months. Methods A multicenter analysis was performed in 10 secondary and tertiary institutions. Lung function parameters (forced vital capacity ( FVC ), pre‐ and postbronchodilator FEV 1, residual volume ( RV ), and total lung capacity ( TLC ) were determined at baseline and at 6?months. Omalizumab response was assessed at the 6‐month visit. In the omalizumab responder patients, lung function parameters were also obtained at 12, 18, and 24?months. Results Mean prebronchodilator FEV 1 showed improvement in responders at 6?months, while a decrease was observed in nonresponders (+0.2±0.4?L and ?0.1±0.4?L, respectively, P .01). After an improvement at 6?months, pre‐ and postbronchodilator FEV 1 remained stable at 12, 18, and 24?months. The FEV 1/ FVC remained unchanged over time, but the proportion of patients with an FEV 1/ FVC ratio 0.7 decreased at 6, 12, 18, and 24?months (55.2%, 54.0%, 54.0%, and 44.8%, respectively, P .05). Mean RV values decreased at 6?months but increased at 12?months and 24?months ( P .05). Residual volume/total lung capacity ( RV / TLC ) ratio decreased at 6?months and remained unchanged at 24?months. Conclusion After omalizumab initiation, FEV 1 improved at 6?months in responder patients and then remained stable for 2?years. RV and RV / TLC improved at 6?months.

机译：摘要背景omalizumab，抗IgE抗体，用于治疗严重过敏性哮喘的患者。随着时间的推移肺功能参数的演变和omalizumab响应者和非响应者患者之间的差异仍然不确定。这个现实生活研究的目的是将强制呼气量的变化进行比较omalizumab响应者的第二（FEV 1）和6个月的非反应者。方法在10个二级和三级机构中进行多中心分析。肺功能参数（强制生命能力（FVC），预先生和后伯丙酮（RV），残余体积（RV）和总肺容量（TLC）在基线和6个月内测定。在6个月的6个月评估omalizumab反应访问。在奥拉姆利亚可响应者患者中，还在12,18和24个月内获得肺功能参数。结果意味着预伯发胆剂FEV 1在6？数月中显示出响应者的改善，而无关的响应者（+ 0.2±0.4 ？L和α0.1±0.4？l，分别p <0.01）。在6月份的改善后，在12,18和24个月内持平，前伯丙替胆剂FEV 1保持稳定。FEV 1 / FVC随着时间的推移保持不变，但FEV 1 / FVC比例的比例在6,12,18和24个月下降0.7个月（55.2％，54.0％，54.0％和44.8％，P＆lt ; 05）。平均rV值在6？几个月下降，但在12个月和24个月和24个月（p <.05）中增加。残留体积/全肺容量（RV / TLC）大鼠IO在6个月下降，在24个月内保持不变。结论omalizumab启动后，FEV 1在响应者患者中的6个月改进，然后保持稳定2岁。 RV和RV / TLC在6个月内得到改善。

著录项

来源
《Allergy》 |2017年第12期|共9页
作者
Paganin F.; Mangiapan G.; Proust A.; Prudhomme A.; Attia J.; Marchand‐Adam S.; Pellet F.; Milhe F.; Melloni B.; Bernady A.; Raspaud C.; Nocent C.; Berger P.; Guilleminault L.;
展开▼
作者单位

INSERM U 600 UMR 6212Université de la Méditerranée.Marseille France;

Service de PneumologieCHIC de CréteilCréteil France;

Service de PneumologieCHU de NimesTarbes France;

Service de PneumologieCHG de BigorreTarbes France;

Cabinet de PneumologieBastia France;

Service de PneumologieCHU de ToursTours France;

Cabinet de PneumologieBordeaux France;

Service de PneumologiePolyclinique des FleursOllioules France;

Service de PneumologieCHU de LimogesLimoges France;

Service de PneumologieCentre médical Toki EderCambo les Bains France;

Service de PneumologieClinique PasteurToulouse France;

Service de Pneumologie et d'allergologieCH de la c?te BasqueBayonne France;

Centre de Recherche Cardio‐thoracique de BordeauxUniv. Bordeaux U1045 CIC1401Bordeaux France;

Université de la RéunionSt Denis France;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类医学免疫学;
关键词
asthma; FEV 1; lung function; omalizumab;

机译：哮喘;FEV 1;肺功能;omalizumab;

相似文献

外文文献
中文文献
专利

1. Lung function parameters in omalizumab responder patients: An interesting tool? [J] . Paganin F., Mangiapan G., Proust A., Allergy . 2017,第12期

机译：omalizumab响应者患者中的肺功能参数：一个有趣的工具？
2. Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma [J] . Pilon Dominic, Kavati Abhishek, Ortiz Benjamin, Allergy and asthma proceedings . 2018,第2期

机译：奥拉姆利兹患者过敏性哮喘患者的胃中利兹引发后哮喘控制，肺功能，症状和皮质类固醇诱导
3. SIGNIFICANT IMPROVEMENT IN LUNG FUNCTION FOLLOWING 16 WEEKS OF OMALIZUMAB TREATMENT: POOLED ANALYSES IN PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA [J] . NICOLA HANANIA, BOB LANIER, AHMAR IQBAL, Chest: The Journal of Circulation, Respiration and Related Systems . 2018,第4期

机译：在奥马拉姆的16周后肺功能的显着改善：中度至严重过敏性哮喘患者的汇总分析
4. Adjustable respiratory mechanical parameters lung system for medical patient simulator [C] . Zhonghai He, Guangshuai Zhu International conference on frontiers of manufacturing and design science . 2011

机译：用于医疗模拟病人的可调呼吸机械参数肺系统
5. Immune functions of alveolar macrophages and peripheral blood monocytes in patients with lung cancer: Studies of local versus systemic immunity [D] . Siziopikou, Kalliopi P. 1991

机译：肺癌患者肺泡巨噬细胞和外周血单核细胞的免疫功能：局部和全身免疫研究
6. Multistate Statistical Modeling: A Tool to Build a Lung Cancer Microsimulation Model That Includes Parameter Uncertainty and Patient Heterogeneity [O] . Mathilda L. Bongers, Dirk de Ruysscher, Cary Oberije, -1

机译：多状态统计建模：建立包括参数不确定性和患者异质性在内的肺癌微观模拟模型的工具
7. HIT Poster session 1P154Preclinical diastolic dysfunction is related to impaired endothelial function in patients with chronic kidney diseaseP155Early detection of left atrial and left ventricular abnormalities in hypertensive and obese womenP156Right ventricle preserved systolic function irrespective of right ventricular hypertrophy and disease severity in anderson fabry diseaseP157Left atrial volume and function in patients undergoing percutaneous mitral valve repairP158Impact of left ventricular dysfunction on outcomes of patients undergoing direct TAVI with a self-expanding bioprosthesisP159Anatomic Doppler spectrum – retrospective spectral tissue Doppler from ultra high frame rate tissue Doppler imaging for evaluation of tissue deformationP160Phasic dynamics of ischaemic mitral regurgitation after primary coronary intervention in acute myocardial infarction: serial echocardiographic assessment from emergency room to long-term follow-upP161Reproducibility of 3DE RV volumes - novel insights at a regional levelP162Pulmonary vascular capacitance as assessed by echocardiography in pulmonary arterial hypertensionP163Three-dimensional endocardial area strain: a novel parameter for quantitative assessment of global left ventricular systolic functionP164Role of exercise hemodynamics assessed by echocardiography on symptom reduction after MitraClipP165Early identification of ventricular dysfunction in patients with juvenile systemic sclerosisP166Heart failure with and without preserved ejection fraction - the role of biomarkers in the aspect of global longitudinal strainP167Complex systolic deformation of aortic root: insights from two dimensional speckle tracking imageP168Volumetric and deformational imaging usind 2d strain and 3d echocardiography in patients with pulmonary hypertensionP169Influence of pressure load and right ventricular morphology and function on tricuspid regurgitation in pulmonary arterial hypertensionP170Left ventricular myocardial diastolic deformation analysis by 2D speckle tracking echocardiography and relationship with conventional diastolic parameters in chronic aortic regurgitationP171Extracellular volume, and not native T1 time, distinguishes diffuse fibrosis in dilated or hypertrophic cardiomyopathy at 3TP172Left atrial strain is significantly reduced in arterial hypertensionP173Symptomatic severe secondary mitral regurgitation: LV enddiastolic diameter (LVEDD) as preferable parameter for risk stratificationP174Left ventricular mechanics in isolated left bundle branch block at rest and when exercising: exploration of the concept of conductive cardiomyopathyP175Assessment of myocardial scar by 2D contrast echocardiographyP176Chronic pericarditis - expression of a rare disease: Erdheim Chester diseaseP177Aortic arch mechanics with two-dimensional speckle tracking echocardiography to estimate the left ventricular remodelling in hypertensive patientsP178Strain analysis by tissue doppler imaging: comparison of conventional manual measurement with a semi-automated approachP179Distribution of extravascular lung water in heart failure patients assessed by lung ultrasoudP180Surrogate markers for obstructive coronary artery diseaseP181LA deformation and LV longitudinal strain by two-dimensional speckle tracking echocardiography as predictors of postoperative AF development after aortic valve replacement in ASP182Left ventricular diastolic dysfunction in type 2 diabetic patients with non alcoholic fatty liver diseaseP183Myocardial strain by speckle-tracking and evaluation of 3D ejection fraction in drug-induced cardiotoxicity's approach in breast cancer [O] . AB Gevaert, A Borizanova, F Graziani, 2015

机译：HIT墙报1P154Preclinical舒张功能障碍的慢性肾脏diseaseP155Early检测左心房的相关内皮功能受损，左心室异常，高血压和肥胖womenP156Right心室收缩功能正常，不论右心室肥厚和疾病严重程度在安德森法布里diseaseP157Left房容积和经皮二尖瓣修复患者的功能左心室功能障碍与自膨胀生物升降术患者患者患者的结果，来自超高帧速率组织多普勒成像的患者，用于评估缺血二尖瓣复发的组织变形P160平面动力学后在急性心肌梗死冠脉介入干预：从急诊室到三维超声心动图右心室体积的长期跟踪upP161Reproducibility串行超声心动图评价 - 小说由肺动脉高压肺动脉高压术中超声心动图评估的区域SEATP162玻璃血管电容的见解随着少年全身硬化肺源肌腱肌肤，无需保存的射血分数 - 生物标志物在全球纵向菌株的角色在全球纵向菌株P167比分中的一个主动脉根系中的内容：来自二维散斑跟踪Imagep168散热和变形成像的见解，肺高压患者患者患者患者肺动脉高压患者肺动脉高压肺动脉高压术治疗肺动脉高压术治疗的压力载荷和右心室形态和功能通过2D散斑跟踪超声心动图和与常规舒张性参数的关系分析慢性主动脉率高，而不是天然T1的时间，在3TP172LEFT心房菌株中区分扩张或肥厚性心肌病的扩散纤维化在动脉高压症中显着降低了，在动脉高压症P1173例，严重二次二尖瓣重新改善：LV EndDiaal直径（LVEDD）作为休息左侧束分支块中孤立的左束分支块的风险分层P11744444444444444445的概念：探讨了2D对比超声心动图176Chronic心包炎的心肌瘢痕的导电心肌病概念 - 表达罕见具有二维散斑跟踪超声心动图的力学来估算组织多普勒成像的高血压患者左心室重塑：常规人的比较通过半自动方法测量肺血管肺患者肺血管肺水分分布，由肺超声波180surrogalsp181LA变形和LV纵向应变通过二维散斑跟踪超声心动图作为术后AF的预测因子在ASP182LEFT中更换主动脉瓣膜置换后2型糖尿病患者的心室舒张功能障碍非酒精性脂肪肝病患者P183微囊菌株通过斑点跟踪和评估3D乳腺癌中的3D射血分数的评估

Lung function parameters in omalizumab responder patients: An interesting tool?

摘要

著录项

相似文献

相关主题

期刊订阅